Literature DB >> 32572666

Correction to: The old CEACAMs find their new role in tumor immunotherapy.

Zi-Wen Han1,2, Zhi-Wu Lyv3, Bin Cui3, Ying-Ying Wang1,2, Jun-Ting Cheng1,2, Ying Zhang1,2, Wen-Qi Cai1,2, Yang Zhou1,2, Zhao-Wu Ma1,2, Xian-Wang Wang1,2,4, Xiao-Chun Peng1,2,5, Shu-Zhong Cui6, Ying Xiang7,8, Mo Yang9, Hong-Wu Xin10,11.   

Abstract

Correction is needed to the original version of this article.

Entities:  

Year:  2020        PMID： 32572666     DOI： 10.1007/s10637-020-00967-6

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  2 in total

Review 1.  Tumor buster - where will the CAR-T cell therapy 'missile' go?

Authors:  Chunrun Qu; Hao Zhang; Hui Cao; Lanhua Tang; Haoyang Mo; Fangkun Liu; Liyang Zhang; Zhenjie Yi; Lifu Long; Luzhe Yan; Zeyu Wang; Nan Zhang; Peng Luo; Jian Zhang; Zaoqu Liu; Weijie Ye; Zhixiong Liu; Quan Cheng
Journal:  Mol Cancer       Date:  2022-10-19       Impact factor: 41.444

Review 2.  DNA barcode to trace the development and differentiation of cord blood stem cells (Review).

Authors:  Mo-Yu Wang; Yang Zhou; Guang-Shun Lai; Qi Huang; Wen-Qi Cai; Zi-Wen Han; Yingying Wang; Zhaowu Ma; Xian-Wang Wang; Ying Xiang; Shu-Xian Fang; Xiao-Chun Peng; Hong-Wu Xin
Journal:  Mol Med Rep       Date:  2021-10-13       Impact factor: 2.952
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.